Portable Ultrasound Market (2026-2036)

The growth of this market is mainly driven by on-device artificial intelligence applications cleared for diagnostic indications that convert a probe into a subscription relationship, enterprise software agreements that now generate more revenue than device sales at the leading handheld supplier, silicon transducer technology that removes the cost structure of piezoelectric arrays, clinician shortages that make real-time scan guidance a staffing solution rather than an imaging feature, and the extension of scanning from the imaging department into emergency, critical care and community settings. However, a Chinese hospital capital expenditure contraction that cut the imaging revenue of the largest regional manufacturer by 18.02%, device revenue that is flat to declining even at suppliers reporting overall growth, distributor channel weakness in international markets, and reimbursement that remains tied to the study rather than to the software restrain the growth of this market.

Beyond these, home and community care scanning, wearable and wireless transducers, original equipment manufacturer integration of silicon imaging modules, and clinical decision support cleared for autonomous interpretation are expected to create significant growth opportunities for the stakeholders in this market.

Portable ultrasound is diagnostic imaging taken to the patient rather than the patient taken to imaging. The market comprises devices, spanning portable cart-based systems, laptop and tablet-based systems, handheld probe-based systems, transducers and emerging wearable and wireless systems; the software and artificial intelligence services that run on or alongside them; coupling gels and consumables; and accessories including probe covers, needle guides, cases, stands and batteries. Fixed cart-based radiology ultrasound installed in an imaging department, and the clinical services delivered using portable equipment, fall outside the measurement.

This edition preserves the product, portability, technology, application and end-user structure of the preceding edition and makes two corrections. The first is scope. The earlier edition measured devices, gels and accessories, with no software or artificial intelligence services segment, at a time when that layer was immaterial. It no longer is. Butterfly Network reported second-quarter 2026 software and other services revenue of USD 16.9 million against product revenue of USD 15.7 million, so the omitted segment is now larger than the device segment at the leading pure-play supplier. The second correction is the base: USD 2.24 billion for 2024 under-counts portable cart and tablet systems and the Chinese, Korean and Japanese supplier base.

The preceding edition also segmented by display, dividing black and white from coloured systems. That distinction no longer discriminates between products, because colour Doppler is standard across every current portable platform including handheld probes priced below three thousand dollars. This edition replaces it with transducer technology, which does discriminate: piezoelectric arrays against silicon capacitive and piezoelectric micromachined transducers. Exo describes the Iris handheld device as built on novel silicon-based hardware, and Butterfly identified a next-generation probe together with P5 and Apollo chips and fourth-generation technology among its forward-looking programmes. Transducer fabrication, not display colour, now determines cost structure and form factor.

The ecosystem begins with semiconductor foundries and piezoelectric ceramic suppliers, whose output sets the cost floor for the transducer. Device manufacturers divide into three groups: the imaging majors including GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems and FUJIFILM Sonosite, which sell portable systems alongside fixed installations; the Asian volume manufacturers including Mindray, SonoScape, CHISON, EDAN, Vinno, Wisonic and SIUI; and the handheld specialists including Butterfly Network, Exo Imaging, Clarius, EchoNous and Healcerion. Around them sit artificial intelligence software developers, cloud image management providers, distributors and dealers, and the clinicians, hospitals, ambulatory centres and community programmes that operate the equipment.

Demand is driven first by artificial intelligence cleared for diagnostic indications, because clearance converts software from a feature into a billable product. Exo announced on 18 June 2025 the first FDA 510(k) clearance for artificial intelligence detecting pleural effusion and consolidation or atelectasis, bringing the total of cleared indicators on Exo Iris to 14, with all commercialised artificial intelligence running on the device and functioning without an internet connection. Samsung Medison acquired 100% of Sonio, completing on 30 August 2024, whose Detect assistant holds FDA 510(k) clearance and reports sensitivity above 90% in recognising fetal ultrasound views.

The commercial consequence is visible in the mix. Butterfly Network reported second-quarter 2026 revenue of USD 32.6 million, up 39%, within which software and other services revenue reached USD 16.9 million against USD 6.8 million a year earlier while product revenue fell to USD 15.7 million from USD 16.6 million. Gross margin rose to 71.4% from 63.7% and the adjusted EBITDA loss narrowed 78% to USD 1.4 million. Six new enterprise software agreements were signed in the quarter, and full-year guidance was raised to revenue of USD 119 million to USD 123 million. A market in which the leading supplier grows 39% while selling fewer dollars of hardware is not a device market.

The second driver is the clinician shortage, which reframes scan guidance as a staffing solution. Samsung Medison Chief Executive Officer Kyu Tae Yoo linked the Sonio acquisition directly to healthcare staffing shortages that make real-time examination guidance more relevant, and Sonio software assesses image quality during the examination and extracts standard planes from cine clips. Exo Vice President of Clinical Affairs Arun Nagdev described real-time artificial intelligence as a remarkable assist for clinicians at the bedside in detecting markers of pneumonia and tuberculosis. Where guidance substitutes for formal sonography training, the addressable operator population expands well beyond the imaging department.

The third driver is the extension of scanning into settings that have never had imaging. Butterfly Network received provisional FedRAMP authorisation covering the United States Department of Veterans Affairs, expected certification in the third quarter of 2026, and expects the first commercial implementation of Home and Community Care in the second half of 2026 with revenue in the fourth quarter. Regulatory authorisation was also received in Brazil. Each of these opens a care setting rather than a product category, and the equipment specification for a community scanning programme differs from a hospital specification in connectivity and workflow rather than in image quality.

Restraints are concentrated in hardware and in China. Shenzhen Mindray Bio-Medical Electronics reported full-year 2025 revenue of CNY 33.28 billion, down 9.38%, net profit attributable to shareholders of CNY 8.14 billion, down 30.28%, and Medical Imaging segment revenue of CNY 5.72 billion, down 18.02%. Chinese revenue of CNY 15.63 billion fell 22.97% while international revenue of CNY 17.65 billion rose 7.40%, taking overseas revenue above China for the first time at 53.03% of the total. The company attributed the decline to hospital cost reduction under high interest rates and staffing shortages, volume-based procurement and payment reform.

Device revenue is the second restraint, and it is flat even at suppliers reporting strong growth. Butterfly product revenue fell to USD 15.7 million from USD 16.6 million while total revenue rose 39%, and international revenue fell 14% to USD 5.0 million, attributed mainly to lower probe sales to distributors. GE HealthCare reported second-quarter 2026 revenue of USD 5,295 million, up 5.7% with organic growth of only 3.5%, and reaffirmed full-year organic growth guidance of 3.0% to 4.0%. Hardware unit economics are also deteriorating as handheld price points fall, which transfers the margin opportunity to the software attached to the probe.

Reimbursement is the third restraint. Payment remains attached to the imaging study rather than to the software that interpreted it, so a hospital that buys an artificial intelligence subscription recovers the cost through throughput and avoided downstream imaging rather than through a separate payment. That makes the business case dependent on institutional accounting rather than on a billing code, which lengthens the sales cycle and explains why enterprise agreements rather than individual probe sales now carry supplier growth, and why Butterfly counts enterprise software agreements as a headline metric.

Competitive intensity is therefore highest in software and clearance coverage, and lowest in commodity handheld hardware where Chinese and Korean manufacturers compete on price. Differentiation has moved to the number of cleared diagnostic indications, on-device inference without connectivity, enterprise integration and security accreditation, and partner ecosystems: Butterfly reported 11 Butterfly Embedded partners after adding two, and expects three Butterfly Garden partner tools to become commercially available by year end. The imaging majors have responded by absorbing portable ultrasound into broader reporting, with GE HealthCare combining Imaging and Advanced Visualization Solutions into Advanced Imaging Solutions at USD 3,771 million for the quarter.

Regionally, North America holds the largest share because it is where cleared artificial intelligence is monetised, enterprise agreements are signed and federal access is secured. Europe follows on established point-of-care practice in emergency and critical care. Asia-Pacific is the fastest-growing region over the forecast window, driven by India, Southeast Asia and Japan together with a Chinese recovery from a depressed base rather than by continuing Chinese growth. Latin America is opening through regulatory authorisations including Brazil, and the Middle East and Africa remain small but are the settings where guidance-enabled scanning has the greatest unmet clinical need relative to installed imaging capacity.

The Portable Ultrasound Market is valued at USD 4.42 billion in 2026 and is projected to reach USD 11.00 billion by 2036, at a CAGR of 9.5%. The rate reflects a device segment growing in the mid single digits, a gels and accessories segment tracking device volume, and a software and artificial intelligence services segment compounding at several times the market rate from a small base toward a material share of the total by 2036.

Base Year

2025

Historical Years

2023-2024

Forecast Period

2026-2036

Market Size in 2025

USD 4.05 Billion

Market Size in 2026

USD 4.42 Billion

Market Size in 2036

USD 11.00 Billion

CAGR (2026-2036)

9.5%

Largest Product in 2026

Devices

Fastest-Growing Product

Software & AI Services

Largest Portability in 2026

Portable Cart-based Systems

Fastest-Growing Portability

Handheld Probe-based Systems

Largest Transducer Technology in 2026

Piezoelectric Transducers

Fastest-Growing Transducer Technology

Silicon-based CMUT & pMUT Transducers

Largest Imaging Technology in 2026

2D Ultrasound

Fastest-Growing Imaging Technology

3D & 4D Ultrasound

Largest Application in 2026

Cardiovascular

Fastest-Growing Application

Pulmonary & Critical Care

Largest End User in 2026

Hospitals & Clinics

Fastest-Growing End User

Home & Community Care

Largest Business Model in 2026

Capital Purchase

Fastest-Growing Business Model

Subscription & Software-as-a-Service

Largest Distribution Channel in 2026

Distributors & Dealers

Fastest-Growing Distribution Channel

Direct & Enterprise Sales

Largest Region in 2026

North America

Fastest-Growing Region

Asia-Pacific

Segments Covered

Product, Portability, Transducer Technology, Imaging Technology, Application, End User, Business Model, Distribution Channel

Geographies Covered

North America, Europe, Asia-Pacific, Latin America, Middle East & Africa

Countries Covered

U.S., Canada, Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, Nordic Countries, Rest of Europe, China, Japan, India, South Korea, Australia & New Zealand, Southeast Asia, Rest of Asia-Pacific, Brazil, Mexico, Argentina, Rest of Latin America, Saudi Arabia, UAE, Israel, Turkey, Egypt, South Africa, Rest of Middle East & Africa

Key Companies Profiled